Development, pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
Lutetium-177 (177Lu)-prostate specific membrane antigen (PSMA)-617 is a small-molecule radioligand therapy (RLT) drug targeting PSMA. By selectively delivering the β－ radiation emitted by 177Lu to PSMA-positive prostate cancer cells, it induces tumor cell death. The agent has been approved in multip...
Збережено в:
| Автори: | , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Shanghai Chinese Clinical Medicine Press Co., Ltd.
2026-04-01
|
| Серія: | Zhongguo Linchuang Yixue |
| Предмети: | |
| Онлайн доступ: | https://www.c-jcm.com/article/doi/10.12025/j.issn.1008-6358.2025.20251534 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|